The effectiveness and value of ensifentrine for the treatment of chronic obstructive pulmonary disease

J Manag Care Spec Pharm. 2024 Nov;30(11):1338-1342. doi: 10.18553/jmcp.2024.30.11.1338.
No abstract available

Grants and funding

These authors report that other funding came from Abbott, AHIP, Alnylam, Anthem, Astra Zeneca, Bayer Healthcare, Blue Shield of California, Boehringer-Ingelheim, CRISPR Therapeutics, CVS, Envolve Pharmacy Solutions, Express Scripts, Genentech/Roche, GSK, Harvard Pilgrim Healthcare, Health Care Service Corporation, Humana, Kaiser Permanente, Karuna Therapeutics, LEO Pharma, Mallinckrodt, Merck, Novartis, Novo Nordisk, National Pharmaceutical Council, Otsuka, Pfizer, Premera, Prime Therapeutics, Regeneron, Sanofi, Sun Life Financial, uniQure, and United Healthcare outside the submitted work. Dr. Whittington reports funding from the Institute for Clinical and Economic Review for the conduct of the study; and other research support from the National Pharmaceutical Council and from No Patient Center Behind outside the submitted work; and other personal fees from Genentech outside the submitted work.